AA
RNTX

Ancora Advisors’s Rein Therapeutics RNTX Stock Holding History

Ancora Advisors’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26K Hold
20,000
– – ﹤0.01% 1424
2025
Q4 		$23.2K Buy
+20,000
New +$27.6K ﹤0.01% 1490

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Ancora Advisors's RNTX Position: Q1 2026 in Review

Ancora Advisors held its Rein Therapeutics (RNTX) position steady in Q1 2026 at 20,000 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #1424.

Ancora Advisors first reported a position in RNTX in Q4 2025 and has held it in 2 quarters since. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • Ancora Advisors held 20,000 shares of Rein Therapeutics worth $26K as of Q1 2026.
  • Ancora Advisors left its Rein Therapeutics share count unchanged in Q1 2026.
  • Rein Therapeutics made up ﹤0.01% of Ancora Advisors's portfolio in Q1 2026, its #1424 holding.
  • Ancora Advisors first reported a position in Rein Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Ancora Advisors's 13F filing for Q1 2026, filed 15 May 2026.